Kelly Steven 4
4 · Carisma Therapeutics Inc. · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Kelly Steven
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-06-17+125,000→ 125,000 totalExercise: $1.03Exp: 2034-06-17→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest over two years, with 50% of the shares vesting on June 17, 2025 and the remaining 50% of the shares vesting on June 17, 2026, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.